Merus (MRUS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

MRUS Stock Forecast


Merus stock forecast is as follows: an average price target of $77.86 (represents a 55.29% upside from MRUS’s last price of $50.14) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

MRUS Price Target


The average price target for Merus (MRUS) is $77.86 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $99.00 to $30.00. This represents a potential 55.29% upside from MRUS's last price of $50.14.

MRUS Analyst Ratings


Buy

According to 7 Wall Street analysts, Merus's rating consensus is 'Buy'. The analyst rating breakdown for MRUS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Merus Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 05, 2024Ami FadiaNeedham$85.00$50.1469.53%69.53%
Jun 17, 2024Bradley CaninoStifel Nicolaus$99.00$56.5575.07%97.45%
Jun 04, 2024Asthika GoonewardeneTruist Financial$88.00$52.9466.23%75.51%
Jun 04, 2024Etzer DaroutBMO Capital$91.00$52.9471.89%81.49%
Jun 04, 2024John NewmanCanaccord Genuity$67.00$52.9426.56%33.63%
May 29, 2024Andrew FeinH.C. Wainwright$85.00$54.8754.91%69.53%
May 28, 2024Etzer DaroutBMO Capital$84.00$53.8655.96%67.53%
May 28, 2024Bradley CaninoStifel Nicolaus$90.00$54.8064.23%79.50%
May 24, 2024Asthika GoonewardeneTruist Financial$69.00$60.9913.13%37.61%
May 24, 2024Etzer DaroutBMO Capital$58.00$58.60-1.03%15.68%
Row per page
Go to

The latest Merus stock forecast, released on Aug 05, 2024 by Ami Fadia from Needham, set a price target of $85.00, which represents a 69.53% increase from the stock price at the time of the forecast ($50.14), and a 69.53% increase from MRUS last price ($50.14).

Merus Price Target by Period


1M3M12M
# Anlaysts-210
Avg Price Target-$92.00$81.60
Last Closing Price$50.14$50.14$50.14
Upside/Downside-100.00%83.49%62.74%

In the current month, the average price target of Merus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Merus's last price of $50.14. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 05, 2024NeedhamBuyBuyHold
Jun 26, 2024CitigroupBuyBuyHold
May 29, 2024Bank of America SecuritiesBuyBuyHold
May 28, 2024CitigroupBuyBuyHold
May 28, 2024NeedhamBuyBuyHold
May 24, 2024Cowen & Co.BuyBuyHold
May 24, 2024BMO CapitalOutperformOutperformHold
May 24, 2024H.C. WainwrightBuyBuyHold
Apr 18, 2023NeedhamBuyBuyHold
Nov 16, 2022CitigroupBuyBuyHold
Row per page
Go to

Merus's last stock rating was published by Needham on Aug 05, 2024. The company gave MRUS a "Buy" rating, the same as its previous rate.

Merus Financial Forecast


Merus Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jul 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$11.03M$10.48M$13.50M$10.67M$6.58M-$11.65M$14.71M$13.67M$12.38M$8.35M$9.02M$8.57M$6.06M$6.30M$7.51M-
Avg Forecast$3.66M$2.77M$2.08M$1.71M$13.18M$9.95M$14.71M$7.13M$15.42M$8.76M$8.72M$9.59M$9.60M$9.92M$10.78M$11.29M$9.70M$11.00M$10.62M$9.37M$11.81M$13.14M$8.06M$18.05M$7.57M$7.45M$7.51M$8.53M$7.39M$7.86M
High Forecast$5.10M$3.87M$2.90M$2.38M$18.38M$13.87M$20.51M$9.94M$21.50M$19.23M$12.15M$13.37M$11.97M$13.83M$15.03M$15.74M$13.53M$15.33M$10.62M$13.41M$16.90M$18.81M$11.53M$25.83M$10.83M$10.67M$10.75M$12.20M$10.58M$11.24M
Low Forecast$1.16M$878.54K$658.80K$540.46K$4.18M$3.15M$4.66M$2.26M$4.89M$2.89M$2.76M$3.04M$7.39M$3.14M$3.42M$3.58M$3.07M$3.48M$10.62M$3.08M$3.89M$4.33M$2.65M$5.94M$2.49M$2.45M$2.47M$2.81M$2.43M$2.59M
# Analysts644643744974845443523331112169989
Surprise %-------------1.11%0.97%1.20%1.10%0.60%-1.24%1.25%1.04%1.54%0.46%1.19%1.15%0.81%0.74%1.02%-

Merus's average Quarter revenue forecast for Dec 23 based on 8 analysts is $9.60M, with a low forecast of $7.39M, and a high forecast of $11.97M. MRUS's average Quarter revenue forecast represents a -12.97% decrease compared to the company's last Quarter revenue of $11.03M (Sep 23).

Merus EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jul 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643744974845443523331112169989
EBITDA-------------$-21.89M$-30.54M$-30.72M$-24.00M$-70.94M-$-34.45M$-13.93M$-14.48M$-26.94M$-9.71M$-27.36M$-22.53M$-17.60M$-16.08M$-26.82M-
Avg Forecast$-3.66M$-2.77M$-2.08M$-1.71M$-13.18M$-9.95M$-14.71M$-7.13M$-15.42M$-8.76M$-8.72M$-28.96M$-9.60M$-9.92M$-10.78M$-26.33M$-9.70M$-20.20M$-10.62M$-23.94M$-18.20M$-18.36M$-22.00M$-8.09M$-7.57M$-19.31M$-19.62M$-12.98M$-7.39M$-10.92M
High Forecast$-1.16M$-878.54K$-658.80K$-540.46K$-4.18M$-3.15M$-4.66M$-2.26M$-4.89M$-2.89M$-2.76M$-23.17M$-7.39M$-3.14M$-3.42M$-21.06M$-3.07M$-16.16M$-10.62M$-19.15M$-14.56M$-14.69M$-17.60M$-6.47M$-2.49M$-15.45M$-15.70M$-10.38M$-2.43M$-8.73M
Low Forecast$-5.10M$-3.87M$-2.90M$-2.38M$-18.38M$-13.87M$-20.51M$-9.94M$-21.50M$-19.23M$-12.15M$-34.76M$-11.97M$-13.83M$-15.03M$-31.60M$-13.53M$-24.24M$-10.62M$-28.72M$-21.84M$-22.04M$-26.40M$-9.71M$-10.83M$-23.17M$-23.54M$-15.57M$-10.58M$-13.10M
Surprise %-------------2.21%2.83%1.17%2.47%3.51%-1.44%0.77%0.79%1.22%1.20%3.62%1.17%0.90%1.24%3.63%-

undefined analysts predict MRUS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Merus's previous annual EBITDA (undefined) of $NaN.

Merus Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jul 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643744974845443523331112169989
Net Income-------------$-23.01M$-32.03M$-39.74M$-81.97M$-24.61M-$-18.89M$-14.42M$-14.85M$-27.39M$-10.15M$-27.96M$-23.07M$-17.97M$-16.50M$-26.14M-
Avg Forecast$-55.37M$-54.31M$-55.59M$-60.87M$-53.41M$-53.45M$-57.48M$-52.13M$-43.10M$-50.29M$-43.77M$-29.87M$-43.90M$-44.46M$-47.89M$-27.15M$-54.47M$-20.72M$-34.26M$-24.68M$-18.84M$-18.84M$-22.37M$-8.46M$-29.89M$-19.78M$-20.04M$-13.32M$-27.45M$-11.92M
High Forecast$-6.20M$-6.08M$-6.22M$-6.81M$-5.98M$-5.98M$-6.43M$-5.83M$-4.82M$-43.02M$-4.90M$-23.89M$-30.30M$-4.98M$-5.36M$-21.72M$-6.10M$-16.58M$-34.26M$-19.75M$-15.07M$-15.07M$-17.89M$-6.77M$-3.83M$-15.82M$-16.03M$-10.65M$-3.52M$-9.54M
Low Forecast$-83.74M$-82.15M$-84.08M$-92.06M$-80.78M$-80.84M$-86.94M$-78.85M$-65.19M$-59.78M$-66.20M$-35.84M$-61.84M$-67.24M$-72.43M$-32.58M$-82.38M$-24.86M$-34.26M$-29.62M$-22.61M$-22.60M$-26.84M$-10.15M$-46.65M$-23.73M$-24.04M$-15.98M$-42.84M$-14.31M
Surprise %-------------0.52%0.67%1.46%1.50%1.19%-0.77%0.77%0.79%1.22%1.20%0.94%1.17%0.90%1.24%0.95%-

Merus's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MRUS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Merus SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jul 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643744974845443523331112169989
SG&A-------------$12.59M$16.06M$15.39M$15.28M$12.47M-$11.75M$10.82M$10.17M$10.57M$9.33M$9.72M$9.14M$8.04M$8.88M$12.00M-
Avg Forecast$4.16M$3.15M$2.36M$1.94M$14.98M$11.31M$16.72M$8.10M$17.52M$9.96M$9.91M$10.90M$10.91M$11.27M$12.25M$12.83M$11.03M$12.50M$12.06M$10.64M$13.42M$12.90M$9.16M$7.78M$8.60M$8.47M$8.54M$7.17M$8.40M$4.08M
High Forecast$5.80M$4.39M$3.29M$2.70M$20.89M$15.76M$23.31M$11.30M$24.43M$21.86M$13.81M$15.19M$13.60M$15.71M$17.08M$17.89M$15.37M$17.42M$12.06M$15.24M$19.20M$15.48M$13.10M$9.33M$12.31M$12.12M$12.22M$8.60M$12.02M$4.90M
Low Forecast$1.32M$998.43K$748.71K$614.22K$4.75M$3.58M$5.30M$2.57M$5.55M$3.28M$3.14M$3.45M$8.40M$3.57M$3.88M$4.07M$3.49M$3.96M$12.06M$3.51M$4.42M$10.32M$3.01M$6.22M$2.83M$2.79M$2.81M$5.73M$2.77M$3.27M
Surprise %-------------1.12%1.31%1.20%1.39%1.00%-1.10%0.81%0.79%1.15%1.20%1.13%1.08%0.94%1.24%1.43%-

Merus's average Quarter SG&A projection for Dec 23 is $10.91M, based on 8 Wall Street analysts, with a range of $8.40M to $13.60M. The forecast indicates a -13.33% fall compared to MRUS last annual SG&A of $12.59M (Sep 23).

Merus EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jul 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643744974845443523331112169989
EPS-------------$-0.43$-0.66$-0.86$-2.12$-0.53-$-0.43$-0.46$-0.39$-0.71$-0.28$-0.96$-0.64$-0.54$-0.68$-1.12-
Avg Forecast$-0.90$-0.88$-0.90$-0.98$-0.86$-0.86$-0.93$-0.84$-0.70$-0.81$-0.71$-0.75$-0.71$-0.72$-0.77$-0.94$-0.88$-0.63$-0.59$-0.56$-0.55$-0.53$-0.50$-0.20$-0.52$-0.47$-0.53$-0.52$-0.47$-0.48
High Forecast$-0.10$-0.10$-0.10$-0.11$-0.10$-0.10$-0.10$-0.09$-0.08$-0.70$-0.08$-0.08$-0.49$-0.08$-0.09$-0.10$-0.10$-0.07$-0.59$-0.07$-0.07$-0.07$-0.06$-0.03$-0.07$-0.06$-0.07$-0.07$-0.06$-0.06
Low Forecast$-1.35$-1.33$-1.36$-1.49$-1.31$-1.31$-1.41$-1.27$-1.05$-0.97$-1.07$-1.13$-1.00$-1.09$-1.17$-1.42$-1.33$-0.95$-0.59$-0.88$-0.86$-0.83$-0.78$-0.32$-0.81$-0.73$-0.83$-0.81$-0.74$-0.75
Surprise %-------------0.60%0.85%0.92%2.41%0.85%-0.77%0.84%0.74%1.41%1.37%1.86%1.36%1.02%1.31%2.35%-

According to undefined Wall Street analysts, Merus's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MRUS previous annual EPS of $NaN (undefined).

Merus Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KRONKronos Bio$0.95$7.63703.16%Buy
LYELLyell Immunopharma$1.23$9.50672.36%Hold
ANEBAnebulo Pharmaceuticals$2.08$6.00188.46%Buy
MLYSMineralys Therapeutics$11.76$30.00155.10%Buy
ACRVAcrivon Therapeutics$8.91$21.50141.30%Buy
STROSutro Biopharma$4.50$10.80140.00%Buy
REPLReplimune Group$11.13$24.20117.43%Buy
LRMRLarimar Therapeutics$7.20$14.50101.39%Buy
SNDXSyndax Pharmaceuticals$19.12$36.0088.28%Buy
MRUSMerus$50.14$77.8655.29%Buy
ADAGAdagene$3.49$5.0043.27%Buy
KURAKura Oncology$20.88$28.6737.31%Buy
CRNXCrinetics Pharmaceuticals$53.80$70.1430.37%Buy
PCVXVaxcyte$116.00$124.147.02%Buy
PTGXProtagonist Therapeutics$47.02$50.006.34%Buy
ANABAnaptysBio$40.33$36.33-9.92%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

MRUS Forecast FAQ


Yes, according to 7 Wall Street analysts, Merus (MRUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of MRUS's total ratings.

Merus (MRUS) average price target is $77.86 with a range of $30 to $99, implying a 55.29% from its last price of $50.14. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for MRUS stock, the company can go up by 55.29% (from the last price of $50.14 to the average price target of $77.86), up by 97.45% based on the highest stock price target, and down by -40.17% based on the lowest stock price target.

MRUS's highest twelve months analyst stock price target of $99 supports the claim that Merus can reach $80 in the near future.

Merus's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $44.98M (high $62.7M, low $14.25M), average EBITDA is $-44.976M (high $-14.251M, low $-62.705M), average net income is $-216M (high $-24.227M, low $-327M), average SG&A $51.11M (high $71.26M, low $16.2M), and average EPS is $-3.5 (high $-0.392, low $-5.293). MRUS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $10.22M (high $14.24M, low $3.24M), average EBITDA is $-10.217M (high $-3.237M, low $-14.245M), average net income is $-226M (high $-25.309M, low $-342M), average SG&A $11.61M (high $16.19M, low $3.68M), and average EPS is $-3.656 (high $-0.409, low $-5.53).

Based on Merus's last annual report (Dec 2023), the company's revenue was $43.95M, beating the average analysts forecast of $41.59M by 5.67%. Apple's EBITDA was $-152M, beating the average prediction of $-56.629M by 167.97%. The company's net income was $-155M, missing the average estimation of $-163M by -5.18%. Apple's SG&A was $59.84M, beating the average forecast of $47.27M by 26.59%. Lastly, the company's EPS was $-0.003, missing the average prediction of $-3.139 by -99.90%. In terms of the last quarterly report (Sep 2023), Merus's revenue was $11.03M, beating the average analysts' forecast of $9.92M by 11.24%. The company's EBITDA was $-21.894M, beating the average prediction of $-9.918M by 120.75%. Merus's net income was $-23.012M, missing the average estimation of $-44.461M by -48.24%. The company's SG&A was $12.59M, beating the average forecast of $11.27M by 11.71%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-0.719 by -40.18%